Introduction
Protein C (PC) is a vitamin K-dependent serine protease zymogen produced by the liver. The anticoagulant factor is activated by the thrombin (factor IIa: FIIa)-bound thrombomodulin expressed on the endothelium. Activated PC (aPC) inactivates FVa and FVIIIa in the presence of protein S (PS) as the cofactor. 1 Administration of aPC products inhibits clot formation and augments fibrinolysis by blocking plasminogen activator inhibitor-1. aPC also exerts anti-inflammatory and cytoprotective effects on neutrophils, macrophages, dendritic cells and endothelial cells via specific receptors. 2 Inherited PC deficiency is an autosomal recessive thrombophilia. 1 Homozygotes and compound heterozygotes of PROC mutation present with purpura fulminans (PF) during early neonatal period. 3 Heterozygous PROC-mutated adults are at risk of deep vein thrombosis, pulmonary thromboembolism and disseminated intravascular coagulopathy, being often triggered by infection, vasculopathy and malignancy. Sepsis and liver dysfunction precipitate PC deficiency via the consumption, impaired synthesis and both. Plasma PC activity is physiologically low until 6 months of age. Neonates are vulnerable to vitamin-K-deficient coagulopathy arising from the immaturity, nutrition and enteral microbiota. Nevertheless, there is little information about neonatal thromboembolism arising from non-familial PC deficiency.
We report a case of neonatal asphyxia and renal failure associated with non-inherited PC deficiency. The etiology and management of hypercoagulable crisis in the newborn was discussed.
Case A male newborn was hospitalized because of neonatal asphyxia showing 2 and 7 of Apgar scores at 1 and 5 min, respectively. He was born to a healthy 30-year-old mother, gravida 0 and para 0, at 41 weeks of gestation by urgent caesarean section for nonreassuring fetal status on the labor induction, after uneventful pregnant course. The small-for-gestational age infant weighing 2404 g had normal umbilical cord and placenta. There was no consanguineous marriage or contributory family history. On day 6 after birth, he was transferred to our tertiary neonatal intensive care unit because of anuria and thrombocytopenia.
On admission, the vigorous infant showed 70 min À1 of tachypnea, normal pulse rate (136 min À1 ) and blood pressure (89/67 mm Hg). Body temperature was 37.6 1C. There was no desaturation. He had occipital cephalhematoma and faint purpura (3 Â 5 cm) on the right back. Auscultation was unremarkable. No hepatosplenomegaly was found. Complete blood counts and coagulation study 2 days after the transfusion of packed platelets and fresh frozen plasma (FFP) revealed white blood cells 7.540 Â 10 9 l À1 , hemoglobin 9.9 g dl À1 , platelets 69 Â 10 9 l À1 , fibrinogen 103 mg dl À1 , prothrombin time-INR 1.56, activated partial thromboplastin time 48.1 s, fibrinogen degradation products 15.0 mg ml À1 and D-dimer 7.9 mg ml À1 . Antithrombin activity was 47%, thrombin-antithrombin complex was 7.3 ng ml À1 and plasmin a2-antiplasmin complex was 2.5 mg ml À1 . C-reactive protein concentration was 0.13 mg dl À1 . Serum levels of creatinine (7.54 mg dl À1 ), urea nitrogen (59 mg dl
À1
), uric acid (22.5 mg dl À1 ), aspartate aminotransferase (113 U l À1 ), alanine aminotransferase (345 U l À1 ) and creatinine kinase (904 U l À1 ) were high. Blood gas analysis indicated metabolic acidosis with -7.1 mmol l À1 of actual base excess. Dark red urine indicated hemolysis. Echographies revealed intact brain, heart, liver and kidney.
Intensive therapy was started for renal failure and disseminated intravascular coagulopathy (Figure 1) . Dalteparin, nafamostat mesilate, urinastatin, antithrombin products and FFP but not packed platelets were infused for the hypercoagulability of unknown cause. Diuretics, catecholamine, recombinant human atrial natriuretic peptide and packed red cells were administered. Urine volume slowly increased. Serum creatinine levels at the peak of 9.47 mg dl À1 on day 13 of age decreased gradually. During repeated FFP infusions, low PC activity (33%, reference range (rr): 67-130) was dissociated with subnormal PS activity (61%, rr: 73-121) on day 21 of age. The steady improvement of coagulopathy and renal function after each FFP substitution was suggestive of inherited thrombophilia. The coagulation profile was reassessed after vitamin K therapy and 10 days after the last FFP infusion. PC activity was 6%, PC antigen level was 33% (rr: 65-135) and PS activity was 53%. Protein induced by vitamin K absence or antagonists-II levels (PIVKA-II; 13 mAU ml À1 , rr: p40) and FVII activity (75%, rr: 75-140) were normal. These findings indicated the type 2 PC-deficient heterozygote. Administration of human plasma-derived aPC (Anact C; a bolus infusion of 50 U kg
and a continuous infusion of 50-100 U kg À1 for consecutive 7 days, The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan) led to the drastic increase of platelet counts, undetectable D-dimer and decreasing creatinine levels. Magnetic resonance imaging of the brain and abdomen, scintigraphy of the lung and heart, renogram and funduscopy revealed no infarctions. Direct sequencing of the coding and promoter regions of PROC revealed no mutation in the infant. 4 Healthy father and mother had normal PC activity of 135% and 165%, respectively. Thereafter, PC activity of the patient increased to 55% until the age of 3 months, and attained 102% at the age of 10 months. Serum creatinine levels fell to 0.87 mg dl À1 until 10 months. The infant shows normal development at the writing of the manuscript.
Discussion
The hypercoagulable neonate presented renal failure, cephalhematoma, purpura and hemoglobinuria. Extremely low PC but not PS activity, the response to aPC therapy and no PROC mutation determined the diagnosis of acquired PC deficiency. Despite the low frequency of PROC mutation, the thrombotic risk of PC mutant is higher than other congenital thrombophilias. 5, 6 Neonatal PF is the hallmark of severe PC deficiency (<0.01 U ml À1 or <1% of PC activity). Heterozygous PC-deficient infants are at risk of PF in the association with additional triggers. 4 Cerebral infarction and/or vitreous bleeding were the other presentations of fetal/neonatal PC deficiency. 7 Kidney is a target organ of thrombosis in neonatal thrombophilias. 8 In this context, selective PC deficiency has a greater impact on the thromboembolic events especially in early infancy than other thrombophilias.
The major concern is the etiology of transient PC deficiency in the newborn. Manco-Johnson et al 9 described 11 infants initially seen in the newborn period with undetectable PC activity and/or antigen, which proved on subsequent follow-up, to be acquired. About 5 of the 11 infants manifested thrombotic events, including renal, aortic and cerebral sites. They further evaluated PC, D-dimer and other regulatory proteins in 164 newborn infants. In this report, 10 prevalence of PC <0.1 U ml À1 or <10% of healthy adults ranged from 0 to 37% with the highest rates in twin gestation (either term or preterm) and preterm infants with respiratory distress, and including a rate of 5% in term singleton infants with distress. Although they showed no genetic study, severe to moderately severe PC activity (<0.1 U ml À1 or <10%) could occur and often led to thrombosis in the stressed newborn as noninherited PC deficiency.
At the time of diagnosis, the discrepancy between 6% of PC activity and 33% of PC antigen levels was unexplainable. The lower PC activity than PC antigen levels at first suggested type 2 deficiency, which accounts for 15% of symptomatic deficiency. Genetic PC deficiency arises from a gross deletion in patients with no PROC mutation. 11 However, the qualitative and quantitative abnormality of PC molecule associated with de novo heterozygous PC deficiency was excluded by 102% of PC activity at the age of 10 months. The blood samples at diagnosis showed undetectable PIVKA-II and normal FVII activity. It may raise the possibility that a certain inhibitor selectively reduced the PC activity but not PS activity, while no such factors have been suggested. 12 Shorter half-life of PC and aPC than PS might contribute to persistently low PC activity. To clarify the cause of neonatal PC deficiency, genome-wide study should be directed toward the genotyping associated with the functional maturation of PC activity.
The other issue is the indication of aPC concentrate. The efficacy of aPC therapy is still controversial in the treatment of sepsis and/or PF in childhood. 3, 7 During the disease course, the image analyses disclosed no evidence of thrombosis. However, the early anticoagulant therapy protected irreversible organ damages with impaired circulation. After the start of aPC administration, the increase of platelet counts and disappearance of D-dimer were drastic. Subsequent recovery of renal function might corroborate the additional profibrinolytic and cytoprotective effects of aPC on the ischemic kidney. Although genetic study is indispensable for PC deficiency, the entity of neonatal PC deficiency might emphasize the feasibility of aPC therapy beyond the PROC mutation. Thromboprophylaxis should be augmented for PC-deficient patients. Warfarin control is not easy in young children. In this line, regular PC substitution may be limitedly recommended in early infancy. Further study is needed to search the non-inherited causes of neonatal isolated PC deficiency as well as to establish the optimal aPC therapy for PC-deficient infants.
